

ASX ANNOUNCEMENT MARKET RELEASE

2 April 2025

RESULTS OF GENERAL MEETING

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), a medical technology company focused on commercialising its patented artificial intelligence platform that detects key coronary artery disease imaging markers, advises that the resolutions considered at today's General Meeting of Shareholders were all passed on a poll.

In accordance with listing rule 3.13.2 and section 251AA of the Corporations Act the details of the votes cast on each of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

This announcement was approved by the Artrya Board.

For further information please contact:

Investor Enquiries:

Danny Younis
+61 420 293 042
danny.younis@automicgroup.com.au

Media Relations:

Rama Razy
+61 498 440 142
rama.razy@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com

Disclosure of Proxy Votes

Artrya Limited

General Meeting

Wednesday, 02 April 2025



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 RATIFICATION OF NOVEMBER PLACEMENT SHARES – LISTING RULE 7.1	P	18,882,438	18,829,689 99.72%	26,371 0.14%	2,073,472	26,378 0.14%	19,456,067 99.86%	26,371 0.14%	2,073,472	Carried
2 RATIFICATION OF NOVEMBER PLACEMENT SHARES – LISTING RULE 7.1A	P	18,882,438	18,829,689 99.72%	26,371 0.14%	2,073,472	26,378 0.14%	19,456,067 99.86%	26,371 0.14%	2,073,472	Carried
3 RATIFICATION OF NOVEMBER BROKER OPTIONS	P	24,378,894	24,326,145 99.78%	26,371 0.11%	2,073,472	26,378 0.11%	24,952,523 99.89%	26,371 0.11%	2,073,472	Carried
4 RATIFICATION OF TRANCHE 1 FEBRUARY PLACEMENT SHARES – LISTING RULE 7.1	P	20,673,401	20,598,429 99.64%	48,594 0.24%	2,073,472	26,378 0.13%	21,224,807 99.77%	48,594 0.23%	2,073,472	Carried
5 RATIFICATION OF TRANCHE 1 FEBRUARY PLACEMENT SHARES – LISTING RULE 7.1A	P	20,673,401	20,598,429 99.64%	48,594 0.24%	2,073,472	26,378 0.13%	21,224,807 99.77%	48,594 0.23%	2,073,472	Carried
6 APPROVAL TO ISSUE TRANCHE 2 FEBRUARY PLACEMENT SHARES	P	20,673,401	20,597,919 99.63%	49,104 0.24%	2,073,472	26,378 0.13%	21,224,297 99.77%	49,104 0.23%	2,073,472	Carried
7 APPROVAL TO ISSUE FEBRUARY BROKER OPTIONS	P	24,378,384	24,303,412 99.69%	48,594 0.20%	2,073,982	26,378 0.11%	24,929,790 99.81%	48,594 0.19%	2,073,982	Carried

